The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued products.
GlobalData tracks 85 drugs in development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by 69 companies/universities/institutes. The top development phase for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) is preclinical with 46 drugs in that stage. The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline has 74 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline products market are: Myelo Therapeutics, University of Pittsburgh and Bolder Biotechnology.
The key targets in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline products market include Toll-Like Receptor 5, Nicotinamide Phosphoribosyltransferase, and Nitric Oxide Synthase Inducible.
The key mechanisms of action in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline product include Toll-Like Receptor 5 Agonist with three drugs in Phase I. The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline products include 17 routes of administration with the top ROA being Oral and 14 key molecule types in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline products market including Small Molecule, and Recombinant Protein.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) overview
Radiation toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of ionizing radiation over a very short period of time (usually a matter of minutes). The root cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum; bloody stool; bruising; confusion; dehydration; diarrhea; fainting; and fatigue.
For a complete picture of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
